Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05880667 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adaptive Radiation for Abdominopelvic Metastases

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. 3 versions Re-verified since Sep 19, 2023, no change to tracked fieldsv4-v6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 15, 2023 to Aug 1, 2023
    v3
  3. Start date: Jul 1, 2023 to Aug 15, 2023
    • Study arms: 0 to 1
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
Trial Details
NCT Number NCT05880667
Lead Sponsor Fox Chase Cancer Center
Conditions
(from sponsor)		 Neoplasm - Soft Tissue Pelvis Malignant Secondary, Malignant Neoplasm of Stomach
Related terms Stomach Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov